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Abstract
Introduction Acute myocardial ischaemia and the transition from reversible to irreversible myocardial injury are associ-
ated with abnormal metabolic patterns. Advances in metabolomics have extended our capabilities to define these metabolic 
perturbations on a metabolome-wide scale.
Objectives This study was designed to identify cardiac metabolic changes in serum during the first 5 min following early 
myocardial ischaemia in humans, applying an untargeted metabolomics approach.
Methods Peripheral venous samples were collected from 46 patients in a discovery study (DS) and a validation study (VS) 
(25 for DS, 21 for VS). Coronary sinus venous samples were collected from 7 patients (4 for DS, 3 for VS). Acute myocardial 
ischaemia was induced by transient coronary occlusion during percutaneous coronary intervention (PCI). Plasma samples 
were collected at baseline (prior to PCI) and at 1 and 5 min post-coronary occlusion. Samples were analyzed by Ultra Per-
formance Liquid Chromatography-Mass Spectrometry in an untargeted metabolomics approach.
Results The study observed changes in the circulating levels of metabolites at 1 and 5 min following transient coronary 
ischaemia. Both DS and VS identified 54 and 55 metabolites as significant (P < 0.05) when compared to baseline levels, 
respectively. Fatty acid beta-oxidation and anaerobic respiration, lysoglycerophospholipids, arachidonic acid, docosahexae-
noic acid, tryptophan metabolism and sphingosine-1-phosphate were identified as mechanistically important.
Conclusion Using an untargeted metabolomics approach, the study identified important cardiac metabolic changes in periph-
eral and coronary sinus plasma, in a human model of controlled acute myocardial ischaemia. Distinct classes of metabolites 
were shown to be involved in the rapid cardiac response to ischemia and provide insights into diagnostic and interventional 
targets.
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1 Introduction
Cardiovascular disease (CVD) is the leading cause of 
death in men and women, accounting for approximately 
30% of deaths worldwide (Lopez et al., 2006). The Global 
Burden of Disease study in 2013 estimated that 17.3 mil-
lion deaths worldwide were related to CVD (GBD 2013 
Mortality & Causes of Death Collaborators, 2015). Acute 
coronary syndrome (ACS) represents a spectrum of events 
ranging from unstable angina (UA) and non-ST-elevation 
myocardial infarction (NSTEMI) to ST-elevation myocar-
dial infarction (STEMI), depending on whether there is 
sustained occlusion of the coronary artery by thrombus 
(STEMI), or whether this is transient (NSTEMI). NSTEMI 
is considered to have occurred if biomarkers of myocardial 
injury such as cardiac troponin (cTn) or the MB fraction 
of creatine kinase (CKMB) have been released (Mythili 
& Malathi, 2015). The diagnosis of an ACS has tradi-
tionally included a combination of ischaemic symptoms, 
electrocardiogram (ECG) changes, and elevations in serum 
biomarkers (Adams et al., 1993; Thygesen et al., 2018). 
However, the symptoms can be atypical or absent in many 
patients. ECG changes that aid in the early diagnosis 
may be non-specific or even absent in around 40% of the 
patients (Rouan et al., 1989). As a result, early diagnosis 
of ACS can pose a challenge and relies largely upon serum 
biomarkers, preferably cTn, due to its myocardial tissue 
specificity and their dynamic pattern (Eggers et al., 2004). 
Detection of a rise and /or fall of cTn value with at least 
one value above the  99th percentile upper reference limit, 
when measured at baseline and 3–6 h after clinical presen-
tation, is considered an essential criterion for the diagnosis 
of ACS (Thygesen et al., 2012). Myocardial ischaemia and 
its consequent metabolic alteration is a crucial stage in the 
continuum of ACS which can result in myocyte injury, 
dysfunction, and potential fatal dysrhythmia (Morrow 
et al., 2001; Opie, 1993). Identifying these rapid changes 
in the metabolic pattern may reveal important pathophysi-
ologic mechanisms and potential targets for intervention 
to provide a favorable equilibrium.
Metabolic phenotyping, otherwise known as metabo-
lomics, is a rapidly growing field in systems biology that 
provides the ability to monitor rapid and dynamic meta-
bolic changes in human biofluids and tissues (Dunn et al., 
2011a, 2011b; Holmes et al., 2008). Plasma, a frequently 
examined pool of metabolites, has been the main source 
for metabolic profiling (Fan et al., 2016). The applica-
tion of metabolomics to different models of myocardial 
injury is an emerging field. Metabolomic analysis of serum 
has been used to predict exercise-inducible ischemia 
(Barba et al., 2008; Sabatine et al., 2005). The utility of 
metabolic profiling has also been demonstrated under 
controlled conditions of myocardial ischemia (Lin et al., 
2009). Recently, the predictive value of metabolomics in 
identifying patients at risk of in-stent restenosis (ISR) 
following PCI was demonstrated. Metabolites belonging 
to phospholipid and sphingolipid metabolism classified 
patients with ISR and control subjects with a sensitivity 
and specificity of 91% and 90%, respectively (Cui et al., 
2017). NMR-based metabolomics have also been used to 
identify patients at risk of adverse outcomes and death 
within two years following ACS (Vignoli et al., 2019). 
Much progress has been made in the use of metabolomics 
to identify biomarkers which may aid in the early detection 
and prognosis of ACS (Liu et al., 2020; Pouralijan Amiri 
et al., 2019; Yao et al., 2017). The metabolic profiling of 
peripheral blood samples from 27 patients with UA and 
15 healthy subjects identified hexadecanoic acid, octadeca-
noic acid, 1-deoxyglucose and D-ribofuranose, with 80% 
precision prediction for patients with unstable angina (UA) 
(Shi et al., 2011). Similarly, another study of 45 patients 
with UA and 43 asymptomatic patients with atherosclero-
sis as controls identified phospholipids, including phyto-
sphingosines, phosphatidylcholines and phosphatidylglyc-
erols to be significantly up-regulated in patients with UA 
when compared to controls (Sun et al., 2013). In a more 
recent multicenter prospective study, metabolomic profil-
ing was conducted to identify the metabolic signatures 
associated with future risk of recurrence of angina follow-
ing PCI. The study identified eicosanoids, sphingolipids 
and acylcarnitines as prognostic metabolites in predicting 
patients at risk of recurrence of angina (Cui et al., 2021).
The aim of this study was to evaluate myocardial tissue-
specific metabolic changes in peripheral and coronary sinus 
serum in the first 5 min following acute myocardial ischae-
mia in humans.
2  Materials and methods
2.1  Ethical approval and consent procedures
This study complies with the Declaration of Helsinki and 
was approved by the Manchester Research Ethics Commit-
tee (Ref: 04/Q1406/58) and Central Manchester and Man-
chester Children’s University Hospitals NHS Trust Research 
and Development (PIN:10562). Eligible patients were con-
tacted and provided with patient study information sheet. 
Patients were given sufficient time (minimum 24 h), prior to 
the clinic appointment. The study was discussed during the 
clinic visit when the patients have opportunity to clarify any 
concerns and accept or decline to participate in the study. 
A written consent was obtained for all those who expressed 
their wish to participate in the study.
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2.2  Study population and surgical procedure
This study was based in a tertiary care centre at The Man-
chester Heart Centre and Central Manchester University 
Hospitals National Health Service (NHS) Foundation Trust. 
The study population included a carefully selected cohort of 
stable elective patients with single-vessel coronary artery 
disease. Patients with coronary artery bypass surgery, recent 
acute coronary syndrome (less than six weeks from the pro-
cedure), triple vessel coronary artery disease, left ventricular 
systolic dysfunction, structural heart disease, anaemia, renal 
impairment, chronic inflammatory conditions, and malig-
nancy were excluded.
Blood samples were obtained from 46 patients undergo-
ing elective percutaneous coronary intervention (PCI) to 
native coronary arteries over a period of 8 months. Periph-
eral venous samples were collected through a venous sheath 
inserted into the femoral vein. Coronary sinus sampling was 
performed in 7 patients following cannulation of the coro-
nary sinus using a 6 Fr Amplatz Left-1 catheter (AL-1) dur-
ing the procedures. All the PCI procedures were performed 
via the femoral artery. Most of the participants agreed for 
the peripheral femoral venous sample collection rather than 
coronary sinus sampling due to the less-invasive nature of 
the procedure.
Control samples of venous blood were obtained either 
from the coronary sinus or via the sheath in the femoral 
vein once the guide catheter and guide wire were in position 
before initiation of the PCI procedure (defined as baseline). 
Myocardial ischaemia was generated during the initial bal-
loon inflation to pre-dilate the target lesion during PCI. Bal-
loon inflations of between 30 s and 1 min were performed 
until ECG changes, ST segment depression or ST segment 
elevation and patient symptoms, such as chest tightness 
or pain consistent with myocardial ischaemia were noted. 
Individual operators decided upon the type and size of the 
angioplasty balloon and inflation pressures that were used 
to pre-dilate the target lesions. Serial venous samples were 
collected from either the coronary sinus or femoral vein at 
1 min (defined as TP1) and 5 min (defined as TP5). PCI was 
then completed as per routine.
Patient demographics and procedural data were col-
lected at the time of intervention. Samples were collected 
into EDTA Vacutainer tubes (Becton Dickinson, Franklin 
Lakes, New Jersey) and transported on ice for immediate 
centrifugation at 1500×g for 15 min at 4 °C. Plasma was 
then removed and stored in aliquots at − 80 °C. Two studies 
were undertaken, defined as the Discovery Study (DS) and 
the Validation Study (VS). The process for assignment to the 
DS or VS groups was based on the time of patient recruit-
ment with the first set of patients recruited being assigned 
to the DS group (patients 1–25) and the remaining set of 
patients recruited being assigned to the VS group (patients 
26–46). Peripheral and coronary sinus blood was collected 
from 21 and 4 subjects, respectively, in the DS and from 18 
and 3 subjects in the VS, respectively. Peripheral blood data 
for one subject in the DS group was identified as an outlier 
(the number of metabolite features detected was less than 
35% that of the mean of metabolite features detected across 
all samples) and was removed from the dataset following 
data acquisition.
2.3  Definitions
The epicardial coronary blood vessels consists of left main 
coronary artery branching into left anterior descending 
(LAD) and circumflex (LCx) coronary arteries and the right 
coronary artery (RCA). A coronary atherosclerotic lesion 
of 70% or more is considered significant requiring coronary 
revascularization. The American College of Cardiology/
American Heart Association (ACC/AHA) task force have 
classified the coronary atherosclerotic lesions as A, B and 
C. for predicting success and complications during coronary 
interventions (Ryan et al., 1988). The lesion was defined as 
type A if it was discrete, non-angulated, or non-calcified 
lesion with no major branch involvement. Type B lesions 
were tubular, eccentric, moderately angulated, calcified, 
with bifurcation involvement or ostial location. Type C 
lesions were diffuse, extremely tortuous, calcified, and total 
occlusion for more than 3 months. Based on the classifica-
tion, there is an association of slightly decreasing procedural 
success and increasing procedural risk with lesions staging 
from A to C.
2.4  Metabolic phenotyping
All reagents used were of HPLC grade purity (Sigma-
Aldrich CHROMASOLV, Dorset, United Kingdom). Plasma 
samples were extracted applying liquid–liquid extraction as 
follows: 200 μL aliquots of plasma were mixed with 600 
μL of methanol using a vortex mixer (15 s) followed by 
centrifugation (13,000×g, 15 min). Supernatants were trans-
ferred to Eppendorf tubes and lyophilized (HETO VR MAXI 
vacuum centrifuge attached to a HETO CT/DW 60E cooling 
trap; Jouan, Gydevang, Denmark). A single pooled quality 
control (QC) sample (intra-study QC sample) was prepared 
by pooling 200 μL aliquots of plasma from each sample 
followed by vortex mixing for 60 s. Twenty-two (DS) and 
nineteen (VS) 200 μL aliquots of the intra-study QC sample 
were transferred to separate Eppendorf tubes for extraction 
as described above for the plasma samples.
All samples were analyzed separately in positive and nega-
tive ion modes using Ultra Performance Liquid Chromatogra-
phy-Mass Spectrometry (UPLC-MS) (Waters Acquity UPLC 
system coupled to a Thermo LTQ-Orbitrap XL) applying a 
previously described method (Dunn et al., 2011a, 2011b). 
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Raw data was processed applying the open-source software 
XCMS as previously described (Dunn et al., 2011a, 2011b) 
to construct a data matrix for positive ion mode data and a 
data matrix for negative ion mode data. Signal correction was 
performed to minimize run-order associated drift in response 
by applying quality control-based robust LOESS (locally esti-
mated scatterplot smoothing) signal correction (QC-RLSC) 
(Dunn et al., 2011a, b). Quality assessment and quality-based 
filtering of the data were performed applying the data acquired 
for QC samples only. The relative standard deviation (RSD) 
for QC samples only (from QC sample injection nine onwards) 
and the percentage of QC samples where a response was 
reported were calculated for each metabolite feature. Data for 
all biological samples and QC samples for all metabolites with 
a relative standard deviation for response > 20% in the stud-
ied QC samples and after QC-RLSC were removed from the 
dataset prior to statistical analysis. Data for all biological sam-
ples and QC samples for all metabolites which were detected 
in < 60% of the studied QC samples were removed from the 
dataset prior to statistical analysis. The Wilcoxon signed-rank 
test was applied to peripheral blood sample data only to iden-
tify statistically significant metabolites when comparing base-
line to TP1 samples and baseline to TP5 samples. Metabolites 
were annotated applying the software PUTMEDID_LCMS 
(Brown et al., 2011) to level 2 of the Metabolomics Standards 
Initiative reporting guidelines for chemical analysis (Sum-
ner et al., 2007). Further work to identify several metabolites 
based on MS/MS spectra was also performed with matching 
to an internal retention time and MS/MS library developed 
by Dunn et al. (2011a, 2011b) or to mzCloud (https:// www. 
mzclo ud. org/). Metabolites were grouped into ‘metabolite 
classes’ based on chemical structure similarity (e.g. fatty acids) 
or metabolic pathway similarity (e.g. TCA cycle). Box and 
whisker plots were constructed with MetaboAnalyst using nor-
malized data (Chong et al., 2019). Pathway enrichment analy-
sis was performed using MetaboAnalyst (pathway analysis, 
compound name list inputted, visualization method = scatter 
plot, enrichment method = hypergeometric, topology analy-
sis = relative betweenness centrality, pathway library = homo 
sapiens (KEGG)).
Experimental workflow was identical for samples taken 
from the DS and VS. The metabolomics data acquisition for 
the DS and VS was performed in October 2010 and August 
2011, respectively.
3  Results
3.1  Population demographics
The study population consisted of a cohort of 46 patients; 
25 patients in the DS and 21 patients in the VS. The patient 
characteristics, lesion data, and procedural data are shown 
in Table 1. In both groups, the majority of participants were 
male and Caucasian. There was a large difference in the ves-
sel diameter (range 2.50–2.99 mm) between the DS and VS. 
Apart from this, there were no significant differences in the 
target vessels or lesion types between the studies.
Pre-dilatation of the target lesions was performed with 
angioplasty balloons inflated between 14 to 22 atmospheres 
(mean 15 atmospheres) for a period of between 30 to 60 s 
(mean 31.1  s). During balloon inflation, ischemic ECG 
changes associated with chest discomfort were noted in 
26/46 patients (56.5%), with ST-segment elevation in 19/46 
patients (41.3%), and ST-segment depression in 7/46 patients 
(15.2%). In the remaining 20/46 patients (43.4%), there were 
no ECG changes observed, although 11/20 patients (55.0%) 
reported transient chest discomfort during this period. A 
total of 9 (out of 46) patients did not have ECG changes or 
symptoms during the procedure in whom balloon inflation 
was performed up to the maximum period of 60 s to create 
transient ischaemia. The PCI procedure was then completed 
in all cases, and no major adverse events and complications 
were documented up to 30 days’ post-procedure.
3.2  Metabolomic phenotyping
The metabolic composition of peripheral plasma samples 
collected at baseline, TP1, and TP5 was obtained using 
UPLC-MS. There were 2692 and 1012 metabolite features 
(m/z-RT pairs) detected in positive and negative ion modes, 
respectively, after quality assessment and data filtering in the 
DS. There were 3163 and 919 metabolite features detected 
in positive and negative ion modes, respectively, after the 
same process in the VS. There were 432 and 480 unique 
metabolites annotated in negative ion mode in the DS and 
VS, respectively, with 179 unique metabolites identified in 
both the DS and VS studies. There were 1093 and 1143 
unique metabolites annotated in positive ion mode in the DS 
and VS, respectively, with 384 unique metabolites identified 
in both the DS and VS studies. Following statistical analysis, 
108 and 203 unique metabolites were identified as differing 
(p < 0.05) in the DS and VS, respectively, when comparing 
baseline and TP1 samples; of these, 54 unique metabolites 
were identified as differing (p < 0.05) in TP1 (Supplemen-
tary Table S1). Similarly, 117 and 214 unique metabolites 
were identified as differing (p < 0.05) in the DS and VS, 
respectively, when comparing baseline and TP5 samples; 
of these, 55 metabolites were identified as statistically sig-
nificant in both studies (Supplementary Table S2). There 
were 30 and 77 unique metabolites identified as differing 
(p < 0.05) in the DS and VS, respectively, when compar-
ing TP1and TP5 samples; of these, nine metabolites were 
identified as statistically significant in both studies (Sup-
plementary Table S3).
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Supplementary Tables S1 and S2 highlight classes of 
metabolites where more than one metabolite showed a 
change in both DS and VS. Two acyl carnitines (octanoyl 
carnitine and decanoyl carnitine) showed higher concentra-
tions in baseline samples compared to both TP1 and TP5 
samples. Eleven and twelve fatty acids showed either higher 
or lower concentrations in baseline samples compared to 
both TP1 and TP5 samples in the DS and VS, respectively. 
Boxplots for two examples are shown in Fig. 1A (octanoyl 
carnitine) and Fig. 1B (hexadecanoic acid). C6–C14 fatty 
acids showed a higher concentration at baseline when com-
pared to TP1 and TP5, and C16–C22 fatty acids showed 
a higher concentration at TP1 and TP5 when compared to 
baseline. In addition, eight and twelve lysoglycerophos-
pholipids showed higher concentrations in TP1 and TP5 
samples when compared to baseline samples in the DS and 
VS, respectively (Fig. 2). Two diacylglycerides showed a 
higher concentration at baseline samples when compared to 
TP1 and TP5 samples. Other changes were observed in aro-
matic metabolites, including tryptophan, with six and seven 
metabolites showing a change in the DS and VS, respec-
tively (Fig. 3). These metabolites showed both increases and 
decreases in their concentration when comparing baseline 
to TP1 and TP5 samples. Six short-chain fatty acids also 
showed a statistically significant difference when compar-
ing baseline to TP1 and TP5 samples in both studies with 
increases and decreases in their concentration when com-
paring baseline to TP1 and TP5 samples. Arachidonic acid 
showed a significant upregulation at TP1 and TP5 in both 
sample types (peripheral and coronary sinus) after transient 
coronary ischemia (Fig. 4).   
Robust changes were observed in these and other metabo-
lite classes in both the DS and VS. Acyl carnitines (3 and 3 
metabolites), aromatic metabolites (15 and 20 metabolites), 
bile acids (6 and 7 metabolites), carbohydrates (7 and 12 
metabolites), diacylglycerides (7 and 6 metabolites), fatty 
acids (38 and 31 metabolites), lysoglycerophospholipids 
(25 and 20 metabolites), purine and pyrimidine metabolites 
(7 and 5 metabolites), short-chain organic acids (4 and 5 
metabolites), sterols and steroids (12 and 11 metabolites), 
vitamin D metabolites (6 and 8 metabolites), TCA metabo-
lites (2 and 1 metabolites) and branched-chain amino acid 
metabolism (2 and 1 metabolite) all showed differences in 
one or both of the DS and VS, respectively. Pathway enrich-
ment analysis demonstrated that tryptophan metabolism was 
enriched in two timepoint comparisons, baseline vs. TP1 and 
baseline versus TP5.
The mechanistic relevance of metabolites observed as dif-
fering from baseline in both studies in relation to prior diag-
nosis of diabetes and hypertension, BMI, and ST elevation 
during the procedure was investigated. LysoPC (20:4) was 
higher across all time points in non-diabetic compared to 
diabetic patients (p < 0.05 for TP1). A metabolite annotated 
Table 1  Demographics and clinical profile of the study population
BMI body mass index, ACEi angiotensin-converting enzyme inhibi-
tor, Cx circumflex, CK creatine kinase, DS discovery study, LAD left 
anterior descending, RCA right coronary artery, VS validation study
Bold defines p < 0.05
Baseline variables DS (n = 25) VS (n = 21) p value




 Hypertension 12/25 (48%) 11/21 (52%)
 Diabetes 15/25 (60%) 7/21 (33.3%)
 Hyperlipidemia 22/25 (88%) 19/21 (90.4%)
 Smoking 10/25 (40%) 8/21 (38%)
 BMI (kg/m2) 27.84 ± 5.35 26.47 ± 1.96
Drugs 0.992
 Antiplatelets 25/25 (100%) 21/21 (100%)
 Beta-blockers 20/25 (80%) 16/21 (76.2%)
 ACEi 17/25 (68%) 14/21 (66.6%)
 Statins 25/25 (100%) 21/21 (100%)
 Nitrates 6/25 (24%) 4/21 (19%)
 Calcium channel blockers 6/25 (24%) 7/21 (33.3%)
Lesion characteristics 0.777
 LAD 16/25 (64%) 12/21 (57.1%)
 RCA 6/25 (24%) 7/21 (33.3%)
 Cx 3/25 (12%) 2/21 (9.5%)
Vessel diameter (mm) 0.017
 2.50–2.99 11/25 (44%) 1/21 (4.8%)
 3.00–3.49 7/25 (28%) 8/21 (38%)
 3.50–3.99 6/25 (24%) 8/21 (38%)
 4.50–5.00 1/25 (4%) 4/21 (19%)
Lesion length (mm) 0.993
 10–14 4/25 (16%) 4/21 (19%)
 15–19 5/25 (20%) 5/21 (23.8%)
 20–24 8/25 (32%) 6/21 (28.6%)
 25–30 5/25 (20%) 4/21 (19%)
 > 30 3/25 (12%) 2/21 (9.5%)
Lesion type 0.657
 A 3/25 (12%) 1/21 (4.8%)
 B 10/25 (40%) 10/21 (47.6%)
 C 12/25 (48%) 10/21 (47.6%)
% Stenosis 0.713
 50–74 3/25 (12%) 2/21 (9.5%)
 75–94 15/25 (60%) 15/21 (71.4%)
 > 95 7/25 (28%) 4/21 (19%)
Procedural data
 Mean Ischemic period 31.1 ± 1.87 31.6 ± 3.65
 Median ST elevation 0.5 mm 0.5 mm
 Median ST depression 0.5 mm 0.5 mm
 Mean troponin 0.04 ng/ml 0.03 ng/ml
 Mean CK 102.3 U/L 97.3 U/L
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as 6-(alpha-D-glucosaminyl)-1D-myo-inositol or lactosa-
mine was present at a lower concentration in subjects with 
BMI < 26 compared to subjects with BMI > 26 (p < 0.05 for 
TP5).
4  Discussion
This study has used a metabolomics approach to quantify 
the changes in cardiac metabolite release in response to 
early myocardial ischaemia in humans. We analyzed blood 
samples from the peripheral and coronary sinus plasma in 
the first 5-min period after PCI and demonstrated that dis-
tinct classes of metabolites were involved in the rapid car-
diac response to ischaemia. Several previous studies have 
demonstrated the application of metabolomics to delineate 
the patterns of cardiac metabolism in different models of 
myocardial injury (Barba et al., 2008; Lewis et al., 2008; 
Lin et al., 2009; Sabatine et al., 2005; Teul et al., 2011; 
Turer et al., 2009). However, their greatest limitations are, 
(i) the small number of targeted metabolites studied, and (ii) 
that most of the studies involved myocardial infarction with 
irreversible myocyte injury as opposed to early myocardial 
ischaemia, as investigated in the study reported here. Our 
Fig. 1  Box and whisker plot describing normalized relative intensity 
values in the concentration of octanoyl carnitine (A) and hexadeca-
noic acid (B) at three timepoints (0 = baseline, 1 = TP1 and 5 = TP5) 
for peripheral samples. QC sample data are included (QC). Data for 
the discovery (left) and validation (right) studies are shown (p < 0.05)
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study is interesting for several reasons. Firstly, our unbi-
ased approach identified that the significant metabolic per-
turbations predominantly involved lipid metabolism during 
early cardiac ischaemia. Secondly, only minor fractions of 
the metabolome were altered during early cardiac ischae-
mia suggesting highly specific or highly regulated changes. 
Thirdly, metabolites which have previously been shown to be 
detrimental to cardiac function such as arachidonic acid, as 
well as metabolites which are known to have a cardioprotec-
tive effect such as docosahexaenoic acid, were identified as 
metabolically important following cardiac ischaemia, along 
with other metabolites previously not associated with acute 
ischaemia.
The balance between carbohydrate and fatty acid use as 
substrates in energy production is well reported in associa-
tion with cardiac ischaemia (Li et al., 2012; Oliver, 2015; 
Pascual & Coleman, 2016; Stanley et al., 2005). Ischae-
mia reduces aerobic oxidation of fatty acids and increases 
anaerobic respiration of glucose for ATP synthesis. In our 
study, two acyl carnitines showed a decrease in concentra-
tion following the ischemic event in both the DS and VS 
with eleven and twelve fatty acids demonstrating either an 
increase or decrease in concentration after the ischaemic 
event. It is notable that the same changes were observed in 
coronary sinus samples and in peripheral blood samples. 
This implies that the metabolic changes are myocardial spe-
cific. C6-C14 fatty acids showed a decrease in concentration 
following an ischaemic event whereas C16-C22 fatty acids 
showed an increase in concentration. There were 7 and 6 dia-
cylglycerides along with 38 and 31 fatty acids that showed 
differential concentrations in one of the two studies. These 
data show that there is an increase in the use or a decrease 
in the synthesis of short and medium chain fatty acids, and 
a decrease in the use or an increase in the synthesis of long 
chain and very long chain fatty acids for beta-oxidation. 
Although changes in carbohydrates have been previously 
reported, the analytical method applied is not appropriate 
for a detailed investigation of glucose metabolism, though 
some changes in carbohydrate metabolites were observed.
In our study, eight and twelve lysoglycerophospholipids 
were observed to increase in concentration following the 
ischaemic event in both studies with a further 25 and 20 
lysoglycerophospholipids showing a statistically significant 
change in either the discovery or validation study, respec-
tively. An example is shown in Fig. 2 and the same changes 
were observed in coronary sinus samples and in peripheral 
blood samples implying that the metabolic changes are myo-
cardial specific. Plasma phospholipase A2 cleaves a single 
fatty acid from glycerophospholipids and has been shown to 
increase in the ischaemic myocardium (Leong et al., 1992). 
Lysoglycerophosphocholines (LysoPC) have been reported 
to increase in a model of myocardium starvation and 
ischemia and are markers for incident coronary heart disease 
(Ganna et al., 2014). The modulation of arachidonic acid 
release has been shown to be regulated by LysoPC levels 
in rat heart myoblastic H9c2 cells with an enhanced release 
of LysoPCs associated with palmitoyl (C16:0) or stearoyl 
(C18:0) groups (Golfman et al., 1999). The accumulation 
of LysoPCs has also been linked to dysrhythmia following 
ischaemia (Sobel et al., 1978). Arachidonic acid has been 
shown to increase following an ischaemic event (van der 
Vusse et al., 1982), and in our study population, we found 
that there was significant up-regulation at TP1 and TP5 in 
both sample types (peripheral and coronary sinus) after tran-
sient coronary ischaemia. Arachidonic acid is known to have 
a detrimental effect on cardiac function including through 
potassium channel activation (Kim & Clapham, 1989), leu-
kocyte maintenance (Mullane et al., 1987), and reactive 
Fig. 2  Box and whisker plot describing normalized relative inten-
sity values in the concentration of LysoPC(20:4) at three timepoints 
(0 = baseline, 1 = TP1 and 5 = TP5) for peripheral samples. QC sam-
ple data are included (QC). Data for the discovery (left) and valida-
tion (right) studies are shown (p < 0.05)
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oxygen species production (Cocco et al., 1999). A number of 
studies have found a positive correlation between the amount 
of arachidonic acid and the risk of coronary heart disease; 
for example, Kark et al. (2003) examined an Israeli popula-
tion consuming a diet high in linoleic acid (LA), a precursor 
of arachidonic acid, and reported a relation between risk of 
ACS and adipose tissue arachidonic acid (though not LA) 
(Kark et al., 2003).
In our study, tryptophan metabolism showed a decrease 
in concentration following an ischaemic event, with six and 
seven associated aromatic metabolites showing a statisti-
cally significant difference in both the DS and VS, respec-
tively. Fifteen and 20 aromatic metabolites showed a dif-
ference in only the DS or VS, respectively. This included 
tryptophan, N-formylkynurenine and kynurenine which all 
demonstrated a decrease in relative concentration at TP1 and 
TP5 compared to baseline for the VS study only. Histidine-
Tryptophan-Ketoglutarate (HTK) solution is applied before 
heart transplantation for heart preservation, and higher con-
centrations of tryptophan have shown beneficial effects on 
outcome (Careaga et al., 2001; Lee et al., 2010; Saitoh et al., 
2000).
Importantly, most metabolites shown to differ in their 
concentrations when comparing before and after an acute 
ischaemic event were not known to be associated with BMI, 
diabetes, hypertension or ST elevation during the proce-
dure. This implies that the metabolites discussed above are 
dynamic responders to cardiac ischaemia independent of 
associated risk factors of CVD. Of the limited number of 
statistically significant changes, an unidentified metabolite 
Fig. 3  Box and whisker plot describing normalized relative inten-
sity values in the concentration of tryptophan at three timepoints 
(0 = baseline, 1 = TP1 and 5 = TP5) for peripheral samples. QC sam-
ple data are included (QC). Data for the discovery (left) and valida-
tion (right) studies are shown
Fig. 4  Box and whisker plot describing normalized relative intensity 
values in the concentration of arachidonic acid at three timepoints 
(0 = baseline, 1 = TP1 and 5 = TP5) for peripheral samples. QC sam-
ple data are included (QC). Data for the discovery (left) and valida-
tion (right) studies are shown (p < 0.05)
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showed changes related to BMI and ST elevation during 
PCI. Further studies may be warranted to further investigate 
the mechanistic basis of this observation.
5  Conclusion
This discovery-based mass spectrometry study has defined 
myocardial tissue-specific metabolic changes related to acute 
myocardial ischaemia in the 5-min period after PCI, there-
fore representing rapid tissue-specific metabolic changes to 
the ischemic event. This study has investigated multiple dif-
ferent areas of metabolism simultaneously and has identified 
diverse yet specific areas of metabolism requiring further 
investigation.
5.1  Limitations
There are a number of limitations to the study. It is possi-
ble that some of the changes in metabolites that we report 
to have occurred during transient coronary occlusion may 
relate to vascular trauma rather than ischemia itself. This is 
unlikely as low pressure balloon inflations were employed, 
which are not associated with significant vascular trauma 
(personal intra-vascular imaging observation from MAM). 
Nevertheless, we cannot entirely rule out this possibility.
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